AstraZeneca | Pharma Commons 2012-07-03 11:16:57

Martin Mackay--image courtesy of AstraZeneca AstraZeneca's decision to expand its diabetes partnership with Bristol-Myers Squibb ($BMY) in the wake of the $5.3 billion Amylin buyout is the biggest n…
Read the full story: News